Aden et al. (128) suggest that metabolic network reconstruction and assessment of metabolic profiles of fecal samples could be used to identify patients with IBD likely to achieve clinical remission following anti-TNF therapy. The gene discussed is TNF; the disease is inflammatory bowel disease.